Abatacept and Infliximab May Improve Mortality in Patients Hospitalized with COVID-19 Pneumonia
This study further supports adding another immunomodulatory agent to corticosteroids when treating hospitalized patients with COVID-19 pneumonia. Which agent is best and if multiple agents should be used remains unknown. Stronger evidence supports the use of either IL-6 inhibitors or Janus kinase inhibitors; abatacept or infliximab are unlikely to become recommended on par with these treatments.
Bottom line: Abatacept and infliximab should not replace IL-6 or Janus kinase inhibitors as the recommended non-corticosteroid immunomodulators for treating hospitalized patients with COVID-19 pneumonia.
Citation: O’Halloran JA...
Source: The Hospitalist - February 1, 2024 Category: Hospital Management Authors: Ronda Whitaker Tags: COVID-19 Drug Therapy In the Literature Source Type: research
Clinical Response to Virus-Specific T-Cells Is Not Impacted By T-Cell Co-Stimulation Inhibition
Patients undergoing allogeneic hematopoietic stem cell transplant (HSCT) are at increased risk of viral infections. Virus-specific T cells (VSTs) have been successfully used in the treatment of viral infections that are unresponsive to antiviral therapy. Abatacept is used in the prevention of graft-vs-host disease (GVHD). Abatacept inhibits T cell activation, decreases T cell proliferation, survival and cytokine secretion in vivo. The impact of abatacept on VST outcomes has not been previously studied. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Azada Ibrahimova, Jamie Wilhelm, Adam Lane, Jeremy D. Rubinstein, Stella M. Davies Tags: 607 Source Type: research
Improving Allogenic Hematopoietic Stem Cell Transplantation Equity: Assessing Mismatched Donor Opportunities with Real World Data in a Minority-Rich Cohort
In this study, we examine real-world alternative donor HSCT options for a minority-rich cohort in the Bronx, NY, focusing on the availability of lesser matched (5/8-7/8) donors. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: M Bakri Hammami, Jhannine Alyssa Verceles, Mendel Goldfinger, Nishi Shah, R.Alejandro Sica, Ioannis Mantzaris, Noah Kornblum, Marina Konopleva, Kira Gritsman, Amit Verma, Dennis L. Cooper Tags: 433 Source Type: research
Abatacept Augments Natural Killer Cell Cytotoxicity in Haploidentical HCT: A Novel Approach for Separating GVL and Gvhd.
Abatacept (Abata, CTLA4Ig), was originally explored for blockade of CD28-B7 costimulation pathway in organ transplantation. However, Abata had sparing effect on NK cells, resulting in NK-mediated rejection in preclinical models. We explored this caveat of abatacept to augment NK cell mediated anti-leukemia effect without invoking T cell mediated GVHD, where unmodified DLI were administered 6 hours following administration of Abata in-vivo (Abata-DLI) to patients with R/R leukemia undergoing haploidentical (Haplo)-HCT, on days +7, +21 and +35, resulting in proliferation of mature NK with reduction in both relapse and GVHD. ...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Sarita Rani Jaiswal, Mahak Agarwal, Bhudev C Das, Prakash Baligar, Subhrajit Biswas, Suparno Chakrabarti Tags: 421 Source Type: research
Clinical Burden of GvHD in Patients Receiving CAST for Prophylaxis Following Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplant
Post-transplant cyclophosphamide (PTCy) overcomes the HLA barrier in haploidentical hematopoietic stem cell transplant (HSCT). We recently reported the results of a phase I-II clinical trial investigating the combination of PTCy, abatacept, and a short course of tacrolimus (CAST) for GvHD prophylaxis following peripheral blood haploidentical HSCT. GvHD prevention clinical trials typically report the incidence of GvHD without further details. Here we provide further details on secondary immunosuppression in patients who developed acute or chronic GvHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Peter Tonzi, Jingmei Hsu, Kelli Cole, J Andres-Suarez Londono, Frank Cirrone, Stephanie Wo, Maher Abdul-Hay, Dr. Sharon Gardner, A Samer Al-Homsi Tags: 364 Source Type: research
Abatacept with FluBu2: To Use or Not to Use
In 2021, the FDA approved using abatacept (ABA) for acute graft versus host disease (aGVHD) prevention in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (SCT) from a matched (MUD) or 1 allele-mismatched unrelated donor (MMUD), based on the phase II ABA2 study. In that study, there was no difference in engraftment or relapse between patients who received ABA and those who did not. However, this study included a significant number of young patients (median age (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Luis F Gonzalez-Mosquera, Mrs. Klodiana Neme, Nancy Mikulandric, Izabela Mazur, Josephine Emole, Asif Alavi, Edward Peres, Muneer H. Abidi, Shatha Farhan Tags: 206 Source Type: research
Abatacept and Ptcy with Cyclosporine or Sirolimus As Gvhd Prophylaxis in Haploidentical HCT: Understanding the Immunobiology in Improving the Outcome.
Abatacept (Abata, CTLA4Ig), an inhibitor of a key costimulation pathway has recently been approved for GVHD prophylaxis following unrelated donor HCT in combination with CNI/MTX. Since 2015, we had developed a novel protocol combining Abata and PTCy for HCT from haploidentical family donors. We analysed the impact of donor immunogenetics and immune reconstitution on the long-term outcome of 182 patients receiving HFD-HCT on this protocol. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Sarita Rani Jaiswal, Mahak Agarwal, Prakash Baligar, Hema Malini Aiyer, Bhudev C Das, Subhrajit Biswas, Suparno Chakrabarti Tags: 55 Source Type: research
Reducing Ptcy Dose in Patients Receiving CAST for GvHD Prevention Results in Accelerated Engraftment at the Cost of Higher Incidence of GvHD
We previously reported excellent results of post-transplant cyclophosphamide (PTCy), abatacept (A) and a short course of tacrolimus (T) (CAST) for graft-versus-host (GvHD) prevention following peripheral blood (PB) haploidentical transplant. Mechanistic and preliminary clinical data suggest that the dose of PTCy can be decreased to diminish its toxicity while maintaining its efficacy. We sought to explore the feasibility and efficacy of reduced-dose PTCy in patients (pts) receiving CAST. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: J Andres-Suarez Londono, Kelli Cole, Frank Cirrone, Stephanie Wo, M. Maher Abdul-Hay, Jingmei Hsu, Dr. Sharon Gardner, Mohammad Abu-Zaid, Gloria Contreras Yametti, Benjamin A Levinson, Judith D Goldberg, A. Samer Al-Homsi Tags: LBA-3 Source Type: research
Efficacy and safety of abatacept to treat active birdshot uveitis: a prospective open label interventional proof-of-concept trial
Conclusions
Abatacept is very efficacious to treat both retinal vasculitis and choroiditis in patients with BU and is well tolerated. BCVA and CRT are inadequate to monitor disease activity. On the other hand, CCT is a promising non-invasive tool to detect treatment response in early active BU and dual FA-ICGA Score is very helpful to evaluate retinal vasculitis and choroiditis quantitatively.
Trial registration number
NCT03871361. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - January 29, 2024 Category: Opthalmology Authors: Schauwvlieghe, P., Van Calster, J., Herbort, C. P., Kestelyn, P. A., de Vlam, K. Tags: Open access Intraocular infection and inflammation Source Type: research
The double shared epitope: Its impact on clinical features and ultrasound findings in rheumatoid arthritis
ConclusionsPatients with the double SE exhibited distinct characteristics, increased disease activity, and improved response to abatacept treatment. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - January 26, 2024 Category: Rheumatology Authors: Tohru Michitsuji,
Shoichi Fukui,
Ayako Nishino,
Yushiro Endo,
Kaori Furukawa,
Toshimasa Shimizu,
Masataka Umeda,
Remi Sumiyoshi,
Tomohiro Koga,
Naoki Iwamoto,
Tomoki Origuchi,
Atsushi Kawakami,
Shin ‐ya Kawashiri Tags: ORIGINAL ARTICLE Source Type: research
Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open ‐Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission
ConclusionThe Towards the Lowest Efficacious Dose trial failed to demonstrate NI for the proposed ABA or TCZ tapering strategy. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - January 26, 2024 Category: Rheumatology Authors: Joanna Kedra,
Philippe Dieud é,
Caroline Giboin,
Hubert Marotte,
Carine Salliot,
Thierry Schaeverbeke,
Aleth Perdriger,
Martin Soubrier,
Jacques Morel,
Arnaud Constantin,
Emmanuelle Dernis,
Valérie Royant,
Jean‐Hugues Salmon,
Thao Pham,
Tags: Full Length Source Type: research
Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies
Conclusions
Consistent with the warnings and precautions of the abatacept label, this analysis suggests a potential increase in NMSC risk with abatacept use compared with csDMARDs. No significant increase was observed compared with b/tsDMARDs, but the lower limit of the 95% CI was close to unity. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Simon, T. A., Dong, L., Suissa, S., Michaud, K., Pedro, S., Hochberg, M., Boers, M., Askling, J., Frisell, T., Strangfeld, A., Meissner, Y., Khaychuk, V., Dominique, A., Maldonado, M. A. Tags: Open access, ARD, Rheumatoid arthritis Source Type: research
Species comparison: human and minipig PBMC reactivity under the influence of immunomodulating compounds in vitro
In conclusion, our findings indicate that the effectiveness of suppressive compounds is highly dependent on the stimuli used and must be carefully selected to ensure accurate results. The results highlight the importance of considering the response of T cells in different species when evaluating the potential of an immunomodulatory drug. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - January 9, 2024 Category: Allergy & Immunology Source Type: research
Correction: Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot collaboration
Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration. Annals of the Rheumatic Diseases 2022;81:1358-66.
The scale limit setting in figure 3 has an error, resulting in the omission of two bar plots.
The corrected figure 3 is below:
doi:10.1136/ard-2022–2 22 586 (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Tags: Open access, ARD Correction Source Type: research
